Cancer Letters is an international journal that considers full-length articles and Mini Reviews in the broad area of basic and
translational oncology. Additionally, Special Issues highlight topical areas in cancer research. Basic areas of interest
to a broad readership of Cancer Letters include the molecular genetics and cell biology of cancer, radiation biology,
molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal places
emphasis on experimental therapeutics, particularly targeted therapies for personalized cancer medicine.
Cancer Letters
now offers online submission for authors. Please submit manuscripts at http://www.ees.elsevier.com/can and follow the instructions
on the site.
Benefits to authors
We also provide many author benefits, such as free PDFs, a liberal copyright policy,
special discounts on Elsevier publications and much more. Please click here for more information on our https://www.elsevier.com/authors/journal-authors/author-servicesauthor
services.
Please see our http://www.elsevier.com/journals/cancer-letters/0304-3835/guide-for-authorsGuide
for Authors for information on article submission. If you require any further information or help, please visit our support
pages: http://service.elsevier.com.
https://www.eu.elsevierhealth.com/eu-cancer-letters-03043835.html122710Cancer Lettershttps://www.eu.elsevierhealth.com/media/catalog/product/0/3/03043835_69.jpg00EURInStock/Revues28526128204 <IT>Cancer Letters</IT> is an international journal that considers full-length articles and Mini Reviews in the broad area of basic and
<B>translational oncology</B>. Additionally, Special Issues highlight topical areas in <B>cancer research</B>. Basic areas of interest
to a broad readership of <IT>Cancer Letters</IT> include the molecular genetics and cell biology of <B>cancer</B>, <B>radiation biology</B>,
molecular pathology, <B>hormones</B> and cancer, <B>viral oncology</B>, <B>metastasis</B>, and <B>chemoprevention</B>. The journal places
emphasis on experimental therapeutics, particularly targeted therapies for personalized cancer medicine.
<P><IT>Cancer Letters</IT>
now offers online submission for authors. Please submit manuscripts at <SURL>http://www.ees.elsevier.com/can</SURL> and follow the instructions
on the site.
<P><B>Benefits to authors</B><BR>
We also provide many author benefits, such as free PDFs, a liberal copyright policy,
special discounts on Elsevier publications and much more. Please click here for more information on our <URL><HREF>https://www.elsevier.com/authors/journal-authors/author-services</HREF><HTXT>author
services</HTXT></URL>.
<P>Please see our <URL><HREF>http://www.elsevier.com/journals/cancer-letters/0304-3835/guide-for-authors</HREF><HTXT>Guide
for Authors</HTXT></URL> for information on article submission. If you require any further information or help, please visit our support
pages: <SURL>http://service.elsevier.com</SURL>.
00122709Cancer Letters00https://www.eu.elsevierhealth.com/media/catalog/product/https://www.eu.elsevierhealth.com/media/catalog/product/placeholder/default/generic_item_image_123x160_1_1.pngInStockDomestic1 YearPersonal0304-3835JOURNALELSEVIERIN STOCK0304-3835Volumes 440-467journalsJournalsNoNoNoNoPlease SelectPlease SelectPlease Select
